Schematic overview of key conclusions from the study. Credit: Nature Medicine (2024). DOI: 10.1038/s41591-024-02978-9 Immunotherapy increases survival rates in kidney cancer, but does not work for everyone. A Leuven research team has developed a new method to predict which patients will benefit from it. The team of Francesca Finotello (Computational Biomedicine Group) from the University of Innsbruck also contributed. Their study, published in the journal Nature Medicine, also opens new avenues to even more effective treatments. Every year, roughly 1,300 people in Austria are diagnosed with kidney cancer. Thanks to Read More
No comments:
Post a Comment